Discussion
diabetes
REGRESSION, DIABETES
To our knowledge, this was the first study to investigate the pharmacist-led intervention to improve adherence to iron supplementation after birth. In our research, a novel pharmacist-led intervention that included prescription evaluation and modification, patient-centered medical instruction and counseling, and routine follow-up evaluation was given to premature infants who needed iron supplementation. This research demonstrated that educating and counseling dialysis patients about the use of phosphate binders improved their understanding of the medications, increased their sense of the necessity of the treatment, and decreased their concerns. This beneficial outcome was demonstrated by a level of serum iron (101.36 μg/L) and MEDS scores about 27, with statistically significant than control group.Greater satisfaction with drug information was discovered to be related to the intervention (P = 0.004). Previous research has demonstrated that patient knowledge of medications in people with diabetes (The study team has substantial expertise using the BSID-II to assess neurodevelopment, and both the initial standardization exercises and the quality controls used throughout the study showed strong inter-rater reliability. The BSID-II scores were linked to known risk factors for inadequate neurodevelopment (To establish meaningful associations between the results and interventions, A linear regression analysis was done with corresponding 95% confidence intervals, β coefficients for constant, MEDS, haemoglobin, serum iron and SIMS were 2.944 (2,123-3.764), 0.21 (0.013-0.030), -0.12 (-0.018—0.005), -0.007 (-0.012—0.003) and -0.062 (-0.097—0.026), respectively.In the study, there were a number of limitations. First, this study only included parents who were receiving iron supplements for the first time at a single urban hospital, making it difficult to generalize the results to individuals who were using iron supplements frequently, such as those who had more than two children or resided in rural areas. Second, after initial discharge, some participants might choose to receive follow-up care at other hospitals. Third, because a small percentage of eligible patients declined to participate in the trial, this information was not recorded, making it impossible to report the enrollment rate. Fourth, whereas the other investigator was in charge of postdischarge phone follow-up and iron supplement education, the pharmacist investigator was simply in charge of gathering baseline data and recruiting participants. These pharmacist investigators’ multiple responsibilities could lead to bias (